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ABSTRACT
Schizophrenia (SZ) and bipolar disorder (BD) are severe neuropsychiatric 
disorders with serious impact on patients, together termed “major psychosis”. 
Recently, long intergenic non-coding RNAs (lincRNAs) were reported to play important 
roles in mental diseases. However, little was known about their molecular mechanism 
in pathogenesis of SZ and BD. Here, we performed RNA sequencing on 82 post-
mortem brain tissues from three brain regions (orbitofrontal cortex (BA11), anterior 
cingulate cortex (BA24) and dorsolateral prefrontal cortex (BA9)) of patients with 
SZ and BD and control subjects, generating over one billion reads. We characterized 
lincRNA transcriptome in the three brain regions and identified 20 differentially 
expressed lincRNAs (DELincRNAs) in BA11 for BD, 34 and 1 in BA24 and BA9 for SZ, 
respectively. Our results showed that these DELincRNAs exhibited brain region-specific 
patterns. Applying weighted gene co-expression network analysis, we revealed that 
DELincRNAs together with other genes can function as modules to perform different 
functions in different brain regions, such as immune system development in BA24 and 
oligodendrocyte differentiation in BA9. Additionally, we found that DNA methylation 
alteration could partly explain the dysregulation of lincRNAs, some of which could 
function as enhancers in the pathogenesis of major psychosis. Together, we performed 
systematical characterization of dysfunctional lincRNAs in multiple brain regions of 
major psychosis, which provided a valuable resource to understand their roles in SZ 
and BD pathology and helped to discover novel biomarkers.
INTRODUCTION
Schizophrenia (SZ) and bipolar disorder (BD), 
together termed “major psychosis”, both affect 
approximately 1% of the world’s population and lead to 
severe impact on the life quality of patients [1]. Previous 
studies of SZ and BD mostly focused on the genetic 
factors and identified several disease-associated risk genes 
or variations [2, 3]. High-throughput analysis of gene 
expression profiles also provided additional insight into 
the potential biological processes implicated in SZ and 
BD [4]. However, the biological mechanisms underlying 
the pathophysiology of the disorders still need further 
investigation.
RNA-seq-based transcriptome analyses uncovered 
a large number of long intergenic non-coding RNAs 
(lincRNAs) that are a class of important regulatory 
molecules in gene expression and various diseases [5, 
6]. LincRNAs display prominently spatial and temporal 
expression and show highly specific expression in the 
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brain [7]. Accumulating evidence suggests that lincRNAs 
are implicated in brain evolution, neural development and 
cognitive processes [8]. Recently, the important roles of 
lincRNAs are also revealed in SZ and BD. For example, 
Gomafu, a lncRNA that is associated with alternative 
splicing, was found to contribute to pathogenic splicing 
of SZ-associated genes DISC1 and ERBB4 in SZ patient 
brains [9]. Akula et al. analyzed expression profiles of BD 
patients and identified a differentially expressed lincRNA 
LINC00173 in BD [10]. However, the understanding 
of lincRNAs in major psychosis is still in its infancy. A 
systematical characterization of lincRNA transcriptome 
may help us better understand the pathological mechanism 
of SZ and BD.
In this study, we performed RNA sequencing on 
three brain regions, Brodmann’s Area (BA) 11, BA24 and 
BA9, of 82 postmortem brain samples from SZ and BD 
patients to explore the landscape of lincRNAs in SZ and 
BD. We characterized the lincRNA transcriptomes of these 
three brain regions and identified numerous differentially 
expressed lincRNAs (DELincRNAs).These DELincRNAs 
exhibited strong brain region-specific expression change 
patterns. We identified three dysfunctional lincRNA 
modules based on weighted gene co-expression network 
analysis (WGCNA), revealing that DELincRNAs 
cooperating with important protein-coding genes 
participate in distinct biological processes in different 
brain regions. By analyzing DNA methylation levels 
and histone modification, the dysfunctional mechanisms 
underlying differential expression of lincRNAs were 
further characterized. 
RESULTS
Summary of patient demographics
We performed RNA sequencing on three brain 
regions namely the BA11 (part of orbitofrontal cortex), 
BA24 (part of anterior cingulate) and BA9 (part of 
dorsolateral prefrontal cortex) from SZ and BD patients 
and psychiatrically normal individuals. The demographics 
data of samples used in this study were listed in Table 1. 
In summary, there were 44 BA11 samples from 16 SZ, 16 
BD and 12 control subjects, and 19 BA24 and 19 BA9 
samples from the same subjects including 6 SZ, 7 BD and 
6 controls. There were no significant differences in sex, 
age, postmortem interval (PMI), race or brain PH between 
cases (SZ or BD) and controls (P-value>0.05, t test for 
continuous traits and Fisher’s exact test for categorical 
traits). 
Table 1: Summary of demographics for samples used in this study
Brain Region Demographics Control SZ BD P-value
BA11
Number of Tissue Sample 12 16 16
Sex (males/females) 9/3 11/5 8/8 1.0 (SZ) ; 0.25 (BD)
Age at sample collection 41.8 ± 6.3 39.3 ± 8.9 47.7 ± 9.7 0.40 (SZ) ; 0.06 (BD)
Age at onset NA 23.9 ± 6.2 25.1 ± 7.4
Postmortem Interval (PMI) 30.2 ± 14.2 37.9 ± 18.0 41.9 ± 21.3 0.21 (SZ) ; 0.09 (BD)
Race (w/n) 12/0 16/0 15/1
BrainPH 6.65 ± 0.31 6.49 ± 0.22 6.48 ± 0.20 0.14 (SZ) ; 0.12 (BD)
BA24
Number of Tissue Sample 6 6 7
Sex (males/females) 5/1 4/2 4/3 1.0 (SZ) ; 0.56 (BD)
Age at sample collection 46.5 ± 16.0 55 ± 4.6 46.6 ± 6.0 0.26 (SZ) ; 0.99(BD)
Age at onset NA 25.7 ± 8.1 24 ± 7.4 , NA(2) a
Postmortem Interval (PMI) 24.3 ± 5.1 30.3 ± 5.3 27 ± 7.0 0.07 (SZ) ; 0.44 (BD)
Race (w/h) 5/1 4/2 5/2 1.0 (SZ) ; 1.0 (BD)
BA9
Number of Tissue Sample 6 6 7
Sex (males/females) 5/1 4/2 4/3 1.0 (SZ) ; 0.56 (BD)
Age at sample collection 46.5 ± 16.0 55 ± 4.6 46.6 ± 6.0 0.26 (SZ) ; 0.99(BD)
Age at onset NA 25.7 ± 8.1 24 ± 7.4 , NA(2) a
Postmortem Interval (PMI) 24.3 ± 5.1 30.3 ± 5.3 27 ± 7.0 0.07 (SZ) ; 0.44 (BD)
Race (w/h) 5/1 4/2 5/2 1.0 (SZ) ; 1.0 (BD)
P-values are calculated using t test and Fisher’s exact test for continuous and categorical traits, respectively;
aTwo patients did not record the age at onset. And the mean ± SD are calculated using data of remaining samples;
Race: w denotes for White, h denotes for Hispanic and n denotes for Native American; 
NA, not available; 
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Constructing lincRNA transcriptome in three 
brain regions of SZ and BD
We generated 562, 242 and 238 million reads for 
BA11, BA24 and BA9 samples, respectively, which were 
subsequently mapped to UCSC hg19 human genome. On 
average, there were 12.7 million reads per sample (Table 
S1), which was sufficient to detect differential genes [11]. 
To comprehensively characterize the lincRNA landscape 
in SZ and BD, we obtained 7952 known lincRNAs from 
GENCODE v19 and identified 168 novel lincRNAs 
using a customized computational pipeline based on all 
RNA-seq datasets from the three brain regions (Figure 
S1A, Tables S2-S3, see Supplementary Methods for 
details). After removing lowly expressed lincRNA genes 
and protein-coding genes (PCGs), we constructed the 
transcriptome for each brain region. We identified 1411 
known lincRNAs, 91 novel lincRNAs and 14606 PCGs 
in BA11; 1412, 90 and 14741 in BA24; and 1461, 92 and 
14798 in BA9.
We found that 73.3% of known lincRNAs, 87.6% 
of novel lincRNAs and 95.7% of PCGs expressed in all 
three brain regions, and 15.0% of known lincRNAs, 6.2% 
of novel lincRNAs and 1.9% of PCGs expressed in only 
one brain region (Figure S1B). The expression levels of 
known and novel lincRNAs were lower than PCGs in 
all three brain regions (Figure S1C). These lincRNAs 
had significantly lower coding potential and ORF ratio 
(ratio of ORF size to transcript length) relative to PCGs 
(P-value < 0.001, Wilcoxon rank sum test, Figures 
S1D-E) as measured by CPAT [12]. Moreover, the overall 
lengths of lincRNAs were significantly shorter than PCGs 
(P-value < 0.001, Wilcoxon rank sum test, Figure S1F). 
By calculating the exon sequence conservation using 
phastCons [13], we found that these lincRNAs were less 
conserved than PCGs (P-value < 0.001, Wilcoxon rank 
sum test, Figure S1G). These findings were in agreement 
with previous studies [14].
Brain region-specific dysfunctional lincRNAs 
contribute to the pathogenesis of SZ and BD
We performed differential expression analyses 
in three brain regions by comparing SZ or BD cases to 
controls using DESeq2 [15], edgeR [16] and voom-limma 
[17] (see Materials and Methods section). An outstanding 
study had performed comprehensive evaluation of 
differential gene expression analysis methods for RNA-
seq data. They demonstrated that DESeq and edgeR 
had good performance on detecting differential genes 
with high specificities and sensitivities, while voom-
limma had favorable modeling of genes expressed in one 
condition (i.e. expressed only in cases or only in controls). 
Notably, all the three methods had good control of false 
Figure 1: Differential analyses of lincRNAs in three brain regions for BD and SZ. A. Statistics of differentially expressed 
lincRNAs and PCGs. B. MA-plots for comparisons between BD or SZ cases and controls in corresponding brain regions. Blue circles, 
red triangles and violet rectangles denote differentially expressed (DE) PCGs, known and novel lincRNAs, respectively. C. Heatmap 
representing normalized expression levels of differentially expressed lincRNAs (DELincRNAs) in three brain regions of corresponding 
disease state. D. Heatmap representing normalized JS scores of the DELincRNAs across 16 tissues. E.-G. GSEA plots for enrichment of 
brain-specific lincRNAs in all DELincRNAs (E), DELincRNAs in BA11_BD (F), and DELincRNAs in BA24_SZ (G).
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positive errors [18]. Another study also highlighted that 
employing two or more differential analysis methods 
in parallel could enhance the overall sensitivity to 
detect true positive differential genes [19]. Moreover, 
by comparing the three sets of differential results, we 
found most of the differentially expressed genes were 
identified by more than one algorithm (Figure S2). Thus, 
to maximize identification of potential genes involved in 
BD or SZ, we combined the three algorithms to identify 
differentially expressed genes. As a result, for SZ, 34 
differentially expressed lincRNAs (DELincRNAs) and 
1915 differentially expressed PCGs (DEPCGs) were 
identified in BA24 (BA24_SZ), 1 and 63 in BA9 (BA9_
SZ), and none in BA11 (Figures 1A-B). Specially, we did 
not identify any common DELincRNAs between BA24 
and BA9. For BD, we identified 20 DELincRNAs and 380 
DEPCGs only in BA11 (BA11_BD). When comparing SZ 
and BD, irrespective of brain regions, only one common 
DELincRNA between BA11_BD and BA24_SZ was 
revealed (Figure 1C), while the overlap was significant 
for DEPCGs (P-value < 0.001, Chi-square test). Such 
strong brain region specificity of dysfunctional lincRNAs 
indicated different roles of lincRNAs in different brain 
regions of major psychosis.
The tissue specificity of lincRNAs has been 
widely confirmed. To determine whether these brain 
region-specific DELincRNAs are brain tissue specific, 
we downloaded RNA-seq data from 16 normal tissues. 
Our results showed that these DELincRNAs displayed 
significant brain-specific patterns (Figure 1D-G), 
further supporting their critical roles in maintaining the 
homeostatic functions of the brain [20, 21].
By interrogating DEPCGs, we observed that 
numerous DEPCGs have been found to be associated 
with SZ and BD (P-value < 0.05, Chi-square test, 
Figure S3A). For example, SZ- and BD-related genes 
BDNF [22] and GABRA1 [23] were dysregulated in both 
BA11_BD and BA24_SZ, and SZ-related gene NPY [24] 
was dysregulated in BA9_SZ. In addition, we observed 
significant overlaps (P-value < 0.05, Chi-square test, 
Figures S3B-C) between DEPCGs from our RNA-seq data 
and previous microarray data (GSE12649 and GSE53987 
in GEO database [25] and three datasets in National Brain 
Databank, fold change>1.2). Through GO enrichment 
analysis of DEPCGs, we also identified some functions 
known to be involved in SZ pathology, such as synaptic 
transmission [26], central nervous system development 
[27] and oligodendrocyte differentiation [28] (Figure S4). 
These results provided validations for the differential 
expression of our RNA-seq data.
Taken together, our results showed that 
dysfunctional lincRNAs harbored strong brain and brain 
region specificity, suggesting that they could participate in 
important biological processes in the brain and contribute 
to the pathogenesis of SZ and BD.
Dissecting dysfunctional lincRNA modules in 
major psychosis
In order to explore functional mechanisms of 
lincRNAs in major psychosis, we leveraged the “guilt-
by-association” principle. We attempted to integrate 
individual expression differences of lincRNAs and PCGs 
into a higher order, systems level by applying the WGCNA 
approach [29, 30]. For BA24_SZ, BA9_SZ and BA11_
BD, we identified 5, 4 and 3 significant co-expression 
modules (FDR < 0.05, permutation test, see Materials 
and Methods section) that contained at least one lincRNA 
and showed significant enrichment of DELincRNAs or 
DEPCGs (FDR < 0.05, hypergeometric test), respectively. 
These modules were regarded as dysfunctional lincRNA 
modules.
To explore the roles of the dysfunctional lincRNA 
modules, we estimated over-representation of brain-related 
cell types (Figure 2A, Supplementary Methods). We found 
that dysfunctional lincRNA modules detected in different 
brain regions were enriched for different cell type markers. 
M1 and M2 in BA24_SZ were enriched for neuronal and 
astrocyte markers, respectively. M1 and M4 in BA9_
SZ were enriched for oligodendrocyte and microglia 
markers, respectively. Three modules in BA11_BD were 
all enriched for neuronal markers. Also, we examined 
the relationship between these modules and clinical traits 
including diagnosis, age, sex, race, PMI and brain PH. 
As a result, we found four modules (M1, M2, M3 and 
M5) in BA24_SZ, one module (M1) in BA9_SZ and one 
module (M3) in BA11_BD were associated with disease 
diagnosis without significant influences from confounding 
factors (Figure 2B). Among these disease-related modules, 
M1, M2 and M3 in BA24_SZ and M1 in BA9_SZ were 
significantly enriched by brain-specific lincRNAs (FDR < 
0.25, GSEA, Figure 2C), highlighting the important roles 
of lincRNAs in the pathology of major psychosis. In order 
to further verify their potential disease contributions, we 
then performed GWAS enrichment analyses. As a result, 
M2 in BA24_SZ, M1 in BA9_SZ and M3 in BA11_BD 
(Tables S4-S6) showed significant enrichment of SZ- or 
BD-associated GWAS signals (Figure 2D). 
We next investigated biological processes of the 
modules by performing functional enrichment analyses 
based on PCGs included in the modules (Figure 2E). 
We found that these dysfunctional lincRNA modules 
were involved in some important functions previously 
implicated in SZ and BD. For instance, M2 in BA24_
SZ was involved in immune system development [31], 
negative regulation of neuron differentiation [32] and 
brain development [33]. M1 in BA9_SZ participated in 
oligodendrocyte differentiation [28] and central nervous 
system myelination [34]. M3 in BA11_BD was involved 
in synaptic transmission [35], locomotory exploration 
behavior [36] and activation of innate immune response 
[37]. These dysfunctional lincRNA modules detected 
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Figure 2: Co-expression network analysis of dysfunctional lincRNA modules. A. Enrichment of brain-related cell types. 
Yellow grids indicate significant enrichment of the corresponding cell types in the corresponding modules. For each module, only the most 
significant cell type was given. B. Clinical trait relation. Heatmap representing -log10 transformed P-value of correlation test between 
module eigengenes and clinical traits. Red grids in disease association column represent significant association between the modules and 
corresponding disease while without significant correlation with other clinical traits. C. Enrichment of brain-specific lincRNAs in the 
dysfunctional modules. The upper panel shows the heatmap representing JS scores of lincRNAs and PCGs in the modules. The lower 
panel presents GSEA images indicating significant enrichment of brain-specific lincRNAs in the modules. D. Enrichment test of SZ- or 
BD-associated GWAS signals in the modules. The height of the bars denote -log10(P-value). E. Heatmap representing -log10 transformed 
P-value of functional enrichment analysis. Grey grids indicate NA values.
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in different brain regions seemed to be associated with 
different functions. 
Taken together, our findings suggested that the 
dysfunctional lincRNA modules could contribute 
to psychiatric diseases through influencing different 
brain-related cell types in distinct brain regions, further 
supporting the important roles of lincRNAs in the 
pathology of SZ and BD.
Abnormal epigenetic alterations of differentially 
expressed lincRNAs
DNA methylation is an important regulator of 
transcription and involved in many diseases. We thus 
explored whether the differential expression of lincRNAs 
was caused by DNA methylation alteration. To this end, 
we analyzed our previously detected MeDIP-seq data of 6 
SZ patients and 6 controls. We found three DELincRNAs 
in BA24 and BA9 showing significant methylation 
differences (P-value < 0.05, Wilcoxon ranked sum test, 
Figure 3A). As an example, the promoter of DELincRNA 
ENSG00000229321 showed lower methylation levels in 
SZ patients than in controls (Figure 3B). Consistently, we 
observed an obvious upregulation of ENSG00000229321 
expression in SZ patients compared with controls (P-value 
= 0.001, one-tailed Student’s t-test). Interestingly, two of 
the three differentially methylated DELincRNAs were 
contained in the dysfunctional module M1 of BA24_SZ.
Previous studies have reported the presence of 
lincRNAs with enhancer-like function and their critical 
roles in development and differentiation [38]. To 
determine whether our identified DELincRNAs could 
function as enhancers, we examined the H3K4me3, 
H3K4me1 and H3K27ac signals around the promoters 
of these DELincRNAs in anterior cingulate cortex. As a 
result, we observed significant enrichment of H3K4me3 
and H3K27ac signals at the promoters (Figure 3C). 
Subsequently, we identified 11 enhancer-associated 
DELincRNAs (eDELincRNAs) (Figure 3D, see Materials 
and Methods section), most of which were positively 
correlated with their closest PCGs in SZ (Figure 3E). 
Further, we found that these eDELincRNAs were involved 
in homotypic cell-cell adhesion and regulation of blood 
coagulation by functional analysis of their neighboring 
genes. Molecular pathways involved in neuronal cell 
Figure 3: Epigenetic analysis of DELincRNAs in BA24. A. The heatmap of DNA methylation levels (left) and the corresponding 
ams (right) of promoters of DELincRNAs. B. The UCSC Browser screenshot showing the RNA-seq and MeDIP-seq signals within and 
around DELincRNA ENSG00000229321. C. Histone modification profiles within -10kb to +10kb from TSS of DElincRNAs. D. Pie plot 
showing the percentage of eDELincRNAs in all DELincRNAs. E. Barplots of expression correlations between 7 eDELincRNAs and their 
neighboring genes whose expression data were available.
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adhesion were shown to contribute to SZ susceptibility 
[39]. A population-based cohort study revealed that SZ 
patients exhibited higher risk for developing deep vein 
thrombosis [40], formation of blood clots within deep 
veins. These results indicated that dysfunctional enhancer 
lincRNAs might play a potential role in the etiology of 
major psychosis.
DISCUSSION
We performed RNA sequencing on three brain 
regions to systematically characterize potential roles 
of lincRNAs in SZ and BD. In BD, we identified 
DELincRNAs only in BA11. In SZ, the majority of 
DELincRNAs were identified in BA24. The two brain 
regions orbitofrontal cortex (BA11) and anterior cingulate 
(BA24) have been implicated in the pathology of BD [41] 
and SZ [42], respectively. Moreover, these DELincRNAs 
displayed strong brain-specific expression across different 
tissues. Such strong brain-region and brain specificity of 
DELincRNAs implied important roles of lincRNAs in the 
etiology of major psychosis, and were probably related to 
distinct functional roles of different brain regions in major 
psychosis. In comparison to BA24 in SZ, we identified 
few DELincRNAs (only one) in BA9. A possible 
explanation is that anterior cingulate (BA24) is more 
vulnerable than dorsolateral prefrontal cortex (BA9) in 
SZ [42]. In addition, we compared DELincRNAs between 
SZ and BD, and found only one common DELincRNA. 
In contrast, a significant overlap of DEPCGs between SZ 
and BD was observed, including some known common 
susceptible genes such as BDNF [22] and GABRA1 
[23]. Although similar pathogenesis between SZ and 
BD has been reported in previous studies, most of these 
observations were based on protein-coding genes [43]. 
Our lincRNA analysis results indicated that lincRNAs may 
exert different molecular functions between SZ and BD in 
a brain region-specific way.
Importantly, we revealed several dysfunctional 
lincRNA modules in different brain regions, and found 
that these modules could perform different functions 
in different brain regions. Specially, M2 in BA24_SZ, 
M1 in BA9_SZ and M3 in BA11_BD, which were 
associated with disease states and enriched for disease-
related cell types and GWAS signals, were implicated in 
brain development, oligodendrocyte differentiation and 
locomotory exploration behavior, respectively. These 
three modules were likely to play important roles in the 
pathology of SZ or BD. 
There were 11 dysregulated lincRNAs in the three 
dysfunctional lincRNA modules, including 9 in BA24_SZ, 
1 in BA9_SZ and 1 in BA11_BD. In order to validate 
these lincRNAs, we investigated their expression changes 
in an external data set of 15 schizophrenia, 18 bipolar 
disorder and 18 control samples based on microarray 
profiling (GSE53987). We re-annotated the expression 
of 8 out of the 11 dysregulated lincRNAs among which 
7 (87.5%) were dysregulated with the same direction as 
in our results (Figure S5). The schemes of the structures 
of dysregulated lincRNAs in the three dysfunctional 
lincRNA modules were provided in Figure S6. To explore 
the potential regulation mechanism of DELincRNAs on 
their neighboring genes, we investigated the Hi-C data 
in human neuronal precursor cells [44]. As a result, we 
observed strong chromatin interactions between most of 
the dysregulated lincRNAs and promoter regions of their 
neighboring genes (Figure S7). These results suggested 
that lincRNAs could form chromosome loop with their 
neighboring genes to exert regulation functions.
Among the 151 lincRNAs in M2 in BA24_SZ, 9 
showed differential expression. Functional characterization 
of individual lincRNAs using their highly co-expressed 
PCGs (PCC>0.8) in the module revealed that some 
lincRNAs were associated with ensheathment of neurons, 
myelination and metabolic processes et al. (Figure S8A). 
We noted that DELincRNA ENSG00000260495 was 
presented in this module, which showed strong brain 
specificity (JS score = 0.42), implying a possible origin 
of brain tissue. Interrogating PCGs highly co-expressed 
with ENSG00000260495, we found that although most 
of them located in different chromosomes there were 
still several PCGs locating in the same chromosome 
with ENSG00000260495 (Figure S9F). Moreover, 
ENSG00000260495 was identified as an eDELincRNA, 
and its expression was positively correlated with that of 
its neighboring gene GAN, suggesting a cis-regulation 
mechanism. Interestingly, strong chromatin interaction 
was observed between ENSG00000260495 and the 
promoter region of GAN when investigating Hi-C data 
in human neuronal precursor cells (Figure S7F). The 
structural relation between them provided support for 
the cis-regulation of ENSG00000260495 on GAN. GAN 
has been demonstrated to play a role in neurofilament 
architecture [45] and its instability could cause giant 
axonal neuropathy [46]. Neurofilament subunits NF-L 
and NF-M played crucial roles in sustaining the neuronal 
cytoskeleton and both of them were reported to be 
increased in SZ [47]. Our work provided new targets to 
explore the potential roles of lincRNAs in the pathogenesis 
of major psychosis.
ENSG00000237943 (PRKCQ-AS1) was 
the DELincRNA in M1 in BA9_SZ involved in 
oligodendrocyte differentiation and central nervous 
system myelination (Figure S8B). The functional category 
oligodendrocyte differentiation contained five DEPCGs of 
SZ, including CNP, MYRF, FA2H, CNTN2 and PLP1. CNP 
and QKI, two candidate genes for schizophrenia, have 
been reported to be down-regulated in the schizophrenic 
brain [48, 49]. Although the majority of the PCGs 
highly co-expressed with ENSG00000237943 located in 
different chromosomes (Figure S9J), ENSG00000237943 
was still proved to be an eDELincRNA in our 
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results and transcribed divergently within 1kb of the 
promoter of PRKCQ. Moreover, the expression level 
of ENSG00000237943 in BA9 was highly positively 
correlated with that of PRKCQ (PCC = 0.83) and there was 
strong chromatin interaction between ENSG00000237943 
and the promoter region of PRKCQ (Figure S7J). PRKCQ 
has been identified as a positive regulator in diverse 
cellular signaling pathways and diseases, such as T-cell 
activation and central nervous system autoimmune 
disease [50, 51]. Interestingly, PRKCQ is also involved 
in the differentiation of oligodendrocytes [52]. These data 
suggested that the ENSG00000237943 dysregulation could 
induce oligodendrocyte dysfunction by trans-regulating 
DEPCGs in BA9_SZ_M1 or cis-regulating PRKCQ in SZ.
M3 in BA11_BD contained 9 lincRNAs and 331 
PCGs, among which 1 lincRNA (ENSG00000228794) 
and 19 PCGs were differentially expressed. Notably, 
the DELincRNA ENSG00000228794 was located in 
1p36.33, a region linked with BD [53]. Moreover, 
functional characterization through highly co-expressed 
PCGs (Figure S9K) in the module demonstrated that 
ENSG00000228794 could be involved in calcium ion 
transport (Figure S8C), a critical component of calcium 
signaling. Notably, calcium signaling was found to play 
important roles in modulation of synaptic plasticity 
[54] and was shown to be disturbed in BD [55]. Thus, 
it’s reasonable to assume that ENSG00000228794 
could contribute to pathogenesis of BD and further 
characterization would help better understanding 
molecular mechanisms of BD.
Previous studies have performed comparative 
gene expression analysis between brain tissues and 
peripheral blood samples of schizophrenia patients and 
demonstrated concurrent up-regulation of SELENBP1 
which was proposed as a candidate biomarker for SZ 
[56]. A meta-analysis of peripheral BDNF levels in 
adults with BD revealed consistent reduction of BDNF 
levels and suggested peripheral BDNF as a biomarker 
of mood states and disease progression for BD [57]. 
These findings suggest the potential clinical value of 
investigating gene expression levels in peripheral blood 
samples of major psychosis. Thus, future studies should 
be focused on investigating the dysfunctional lincRNAs 
in peripheral blood samples of major psychosis to identify 
potential lincRNA biomarkers. These candidate lincRNA 
biomarkers could be used to help clinically guide the 
diagnosis and treatment of major psychosis.
In summary, we identified a number of dysregulated 
lincRNAs in SZ and BD, and found their distinct 
contributions in different brain regions. Our findings 
revealed essential functions of lincRNAs in psychiatric 
disorders, helped us understand the molecular mechanisms 
of SZ and BD and further investigation of lincRNAs in 
peripheral blood samples of SZ and BD in the future could 
help identify diagnostic markers.
MATERIALS AND METHODS
Subjects
We obtained 82 post-mortem brain tissues from 
BA11, BA24 and BA9 to conduct RNA sequencing. 
BA11 samples from 16 SZ cases, 16 BD cases and 12 
psychiatrically normal controls were obtained from the 
Array Collection in Stanley Medical Research Institute 
(SMRI) [58] and ethics approval for brain collection was 
held by the SMRI. Tissues from BA24 and BA9 of 6 SZ 
cases, 7 BD cases and 6 controls were retrieved from the 
Southwest Brain Bank [59] with ethics approval from 
the Institutional Review Board of Texas Tech University 
Health Science Center. 
RNA-seq analysis
RNA extraction and sequencing were carried out as 
previously described [59]. Briefly, total RNA was collected 
from brain tissues, which was then used to isolate poly(A) 
mRNA. The mRNA was fragmented to 200~300bp in size 
and reverse-transcribed to cDNA, followed by purification, 
ligation of sequencing adapters and amplification with 
PCR. Libraries were sequenced on Illumina HiSeq 2000 
to generate paired-end 100 bp sequence reads. Raw read 
data were deposited in NCBI Gene Expression Omnibus 
(GEO) under accession number GSE78936. 
RNA-seq reads were mapped to the human reference 
genome (version hg19) using Tophat (version 2.0.13) [60] 
with default parameters. Only uniquely mapped reads 
with no more than two mismatches were retained. Read 
counts for each lincRNA and protein-coding gene (PCG) 
were computed using HTSeq [61]. For each brain region, 
lowly expressed genes (read count < 2 in more than 50% 
of samples) were removed. Additionally, fragments per 
kilobase of transcript per million fragments mapped 
(FPKM) value was calculated for each lincRNA and PCG.
Differential expression analysis
Differential expression between cases (SZ or BD) 
and controls was assessed using three methods including 
DESeq2 [15], edgeR [16] and voom-limma [17]. For each 
brain region, genes with an adjusted P-value of < 0.05 
in at least one method were considered as differentially 
expressed genes.
Functional annotation
We performed Gene Ontology [62] enrichment 
analysis using the hypergeometric distribution test with 
Oncotarget71095www.impactjournals.com/oncotarget
FDR < 0.05, which was implemented in the package 
GOstats [63].
Tissue specificity of lincRNAs
FPKM values of lincRNA genes in 16 normal tissues 
were estimated from RNA-seq data of the Human Body 
Map 2.0. To evaluate the tissue specificity of a lincRNA, 
we calculated the Jensen-Shannon tissue specificity score 
(JS score) for each tissue based on an entropy-based 
metric used by Cabili et al. [64]. A lincRNA was regarded 
to be tissue-specific if the maximal JS score across all 
tissues was over 0.4.
Weighted gene co-expression network analysis
We utilized Weighted Gene Co-expression Network 
Analysis (WGCNA) [29] to identify co-expression 
modules based on lincRNA and PCG expression profiles. 
Permutation test was used to calculate significance (FDR 
< 0.05). The modules with enrichment of differentially 
expressed lincRNAs or PCGs (hypergeometric test, 
FDR < 0.05) and containing at least one lincRNA were 
determined as dysfunctional lincRNA modules. To further 
explore the roles of dysfunctional lincRNA modules, 
we then inspected whether the dysfunctional lincRNA 
modules showed enrichment of brain-related cell types, 
association with disease states and enrichment of SZ- or 
BD-associated GWAS signals [65, 66]. Based on PCGs 
in each module, GO enrichment analysis was performed 
to predict biological functions for the module. See 
Supplementary Methods for details.
Epigenetic analysis
Methylated DNA immunoprecipitation and 
sequencing (MeDIP-seq) of 6 SZ patients and 6 controls 
was performed as previously described [59]. We utilized 
MEDIPS package (version 1.12.0) [67] to quantify the 
methylation levels at the promoters of lincRNAs (2 kb 
upstream and 0.5kb downstream of transcriptional start 
sites). Differential methylation of the DELincRNAs were 
assessed using Wilcoxon rank sum test with P-value 
< 0.05. ChIP-seq data for histone marks H3K4me1, 
H3K4me3 and H3K27ac of BA24 were obtained from the 
NIH Roadmap Epigenomics Program [68] (GSE17312). A 
lincRNA was defined as an enhancer-associated lincRNA 
if its promoter was significantly enriched for H3K27ac 
peaks identified by MACS [69] (P-value < 10-5 with 
default parameters). See Supplementary Methods for 
details.
Statistical analysis
All statistical analyses were performed with R 
software. For comparisons of clinical traits between 
cases and control samples, t-test and Fisher’s exact test 
were performed for continuous and categorical traits, 
respectively. Wilcoxon rank sum test was conducted 
for comparisons between characteristics of lincRNAs 
and protein-coding genes. To calculate the statistical 
significance of overlap between DEPCGs in BA11_BD 
and BA24_SZ and overlap between DEPCGs of this 
study and disease-associated genes from GAD database 
and between DEPCGs of this study and that of previous 
microarray studies, Chi-square test was carried out. For 
enrichment of DEPCGs and DELincRNAs in modules, 
hypergeometric test was performed to assess the statistical 
significance.
ACKNOWLEDGMENTS
This work was supported in part by the National 
High Technology Research and Development Program 
of China [863 Program, Grant Nos. 2014AA021102], 
the National Program on Key Basic Research Project 
[973 Program, Grant Nos. 2014CB910504], the 
National Natural Science Foundation of China [Grant 
Nos. 91439117, 61473106, 61573122], Wu lien-teh 
youth science fund project of Harbin medical university 
[Grant Nos. WLD-QN1407], and Key Laboratory of 
Cardiovascular Medicine Research (Harbin Medical 
University), Ministry of Education.
CONFLICTS OF INTEREST
The authors declare no conflict of interest.
REFERENCES
1. Patel V and Prince M. Global mental health: a new global 
health field comes of age. Jama. 2010; 303:1976-1977.
2. International Schizophrenia C, Purcell SM, Wray NR, 
Stone JL, Visscher PM, O’Donovan MC, Sullivan PF and 
Sklar P. Common polygenic variation contributes to risk of 
schizophrenia and bipolar disorder. Nature. 2009; 460:748-
752.
3. Duan J, Shi J, Fiorentino A, Leites C, Chen X, Moy W, 
Chen J, Alexandrov BS, Usheva A, He D, Freda J, O’Brien 
NL, Molecular Genetics of Schizophrenia c, Genomic 
Psychiatric Cohort c, McQuillin A, Sanders AR, et al. A 
rare functional noncoding variant at the GWAS-implicated 
MIR137/MIR2682 locus might confer risk to schizophrenia 
and bipolar disorder. American journal of human genetics. 
2014; 95:744-753.
4. Zhao Z, Xu J, Chen J, Kim S, Reimers M, Bacanu SA, Yu 
H, Liu C, Sun J, Wang Q, Jia P, Xu F, Zhang Y, Kendler 
Oncotarget71096www.impactjournals.com/oncotarget
KS, Peng Z and Chen X. Transcriptome sequencing and 
genome-wide association analyses reveal lysosomal 
function and actin cytoskeleton remodeling in schizophrenia 
and bipolar disorder. Molecular psychiatry. 2015; 20:563-
572.
5. Guttman M, Donaghey J, Carey BW, Garber M, Grenier 
JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang 
X, Amit I, Meissner A, Regev A, Rinn JL, Root DE, et al. 
lincRNAs act in the circuitry controlling pluripotency and 
differentiation. Nature. 2011; 477:295-300.
6. Batista PJ and Chang HY. Long noncoding RNAs: cellular 
address codes in development and disease. Cell. 2013; 
152:1298-1307.
7. Mercer TR, Dinger ME, Sunkin SM, Mehler MF and 
Mattick JS. Specific expression of long noncoding RNAs 
in the mouse brain. Proceedings of the National Academy 
of Sciences of the United States of America. 2008; 105:716-
721.
8. Qureshi IA and Mehler MF. Emerging roles of non-coding 
RNAs in brain evolution, development, plasticity and 
disease. Nature reviews Neuroscience. 2012; 13:528-541.
9. Barry G, Briggs JA, Vanichkina DP, Poth EM, Beveridge 
NJ, Ratnu VS, Nayler SP, Nones K, Hu J, Bredy TW, 
Nakagawa S, Rigo F, Taft RJ, Cairns MJ, Blackshaw S, 
Wolvetang EJ, et al. The long non-coding RNA Gomafu 
is acutely regulated in response to neuronal activation and 
involved in schizophrenia-associated alternative splicing. 
Molecular psychiatry. 2014; 19:486-494.
10. Akula N, Barb J, Jiang X, Wendland JR, Choi KH, Sen SK, 
Hou L, Chen DT, Laje G, Johnson K, Lipska BK, Kleinman 
JE, Corrada-Bravo H, Detera-Wadleigh S, Munson PJ and 
McMahon FJ. RNA-sequencing of the brain transcriptome 
implicates dysregulation of neuroplasticity, circadian 
rhythms and GTPase binding in bipolar disorder. Molecular 
psychiatry. 2014.
11. Liu Y, Zhou J and White KP. RNA-seq differential 
expression studies: more sequence or more replication? 
Bioinformatics. 2014; 30:301-304.
12. Wang L, Park HJ, Dasari S, Wang S, Kocher JP and Li 
W. CPAT: Coding-Potential Assessment Tool using an 
alignment-free logistic regression model. Nucleic acids 
research. 2013; 41:e74.
13. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, 
Rosenbloom K, Clawson H, Spieth J, Hillier LW, Richards 
S, Weinstock GM, Wilson RK, Gibbs RA, Kent WJ, Miller 
W and Haussler D. Evolutionarily conserved elements 
in vertebrate, insect, worm, and yeast genomes. Genome 
research. 2005; 15:1034-1050.
14. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, 
Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, 
Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, 
Carninci P, et al. The GENCODE v7 catalog of human 
long noncoding RNAs: analysis of their gene structure, 
evolution, and expression. Genome research. 2012; 
22:1775-1789.
15. Love MI, Huber W and Anders S. Moderated estimation of 
fold change and dispersion for RNA-seq data with DESeq2. 
Genome biology. 2014; 15:550.
16. Robinson MD, McCarthy DJ and Smyth GK. edgeR: a 
Bioconductor package for differential expression analysis of 
digital gene expression data. Bioinformatics. 2010; 26:139-
140.
17. Law CW, Chen Y, Shi W and Smyth GK. voom: Precision 
weights unlock linear model analysis tools for RNA-seq 
read counts. Genome biology. 2014; 15:R29.
18. Rapaport F, Khanin R, Liang Y, Pirun M, Krek A, Zumbo 
P, Mason CE, Socci ND and Betel D. Comprehensive 
evaluation of differential gene expression analysis methods 
for RNA-seq data. Genome biology. 2013; 14:R95.
19. Rajkumar AP, Qvist P, Lazarus R, Lescai F, Ju J, Nyegaard 
M, Mors O, Borglum AD, Li Q and Christensen JH. 
Experimental validation of methods for differential gene 
expression analysis and sample pooling in RNA-seq. BMC 
genomics. 2015; 16:548.
20. Kaushik K, Leonard VE, Kv S, Lalwani MK, Jalali S, 
Patowary A, Joshi A, Scaria V and Sivasubbu S. Dynamic 
expression of long non-coding RNAs (lncRNAs) in adult 
zebrafish. PloS one. 2013; 8:e83616.
21. Talkowski ME, Maussion G, Crapper L, Rosenfeld JA, 
Blumenthal I, Hanscom C, Chiang C, Lindgren A, Pereira 
S, Ruderfer D, Diallo AB, Lopez JP, Turecki G, Chen ES, 
Gigek C, Harris DJ, et al. Disruption of a large intergenic 
noncoding RNA in subjects with neurodevelopmental 
disabilities. American journal of human genetics. 2012; 
91:1128-1134.
22. Palomino A, Vallejo-Illarramendi A, Gonzalez-Pinto A, 
Aldama A, Gonzalez-Gomez C, Mosquera F, Gonzalez-
Garcia G and Matute C. Decreased levels of plasma BDNF 
in first-episode schizophrenia and bipolar disorder patients. 
Schizophrenia research. 2006; 86:321-322.
23. Fatemi SH, Folsom TD, Rooney RJ and Thuras PD. 
Expression of GABAA alpha2-, beta1- and epsilon-
receptors are altered significantly in the lateral cerebellum 
of subjects with schizophrenia, major depression and 
bipolar disorder. Translational psychiatry. 2013; 3:e303.
24. Stalberg G, Ekselius L, Lindstrom LH, Larhammar D and 
Boden R. Neuropeptide Y, social function and long-term 
outcome in schizophrenia. Schizophrenia research. 2014; 
156:223-227.
25. Edgar R, Domrachev M and Lash AE. Gene Expression 
Omnibus: NCBI gene expression and hybridization array 
data repository. Nucleic acids research. 2002; 30:207-210.
26. Eastwood SL and Harrison PJ. Markers of glutamate 
synaptic transmission and plasticity are increased in the 
anterior cingulate cortex in bipolar disorder. Biological 
psychiatry. 2010; 67:1010-1016.
27. Katsel P, Davis KL and Haroutunian V. Variations in 
myelin and oligodendrocyte-related gene expression across 
multiple brain regions in schizophrenia: a gene ontology 
Oncotarget71097www.impactjournals.com/oncotarget
study. Schizophrenia research. 2005; 79:157-173.
28. Tkachev D, Mimmack ML, Ryan MM, Wayland M, 
Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH 
and Bahn S. Oligodendrocyte dysfunction in schizophrenia 
and bipolar disorder. Lancet. 2003; 362:798-805.
29. Langfelder P and Horvath S. WGCNA: an R package 
for weighted correlation network analysis. BMC 
bioinformatics. 2008; 9:559.
30. Zhang B and Horvath S. A general framework for weighted 
gene co-expression network analysis. Statistical applications 
in genetics and molecular biology. 2005; 4:Article17.
31. Kinney DK, Hintz K, Shearer EM, Barch DH, Riffin 
C, Whitley K and Butler R. A unifying hypothesis of 
schizophrenia: abnormal immune system development may 
help explain roles of prenatal hazards, post-pubertal onset, 
stress, genes, climate, infections, and brain dysfunction. 
Medical hypotheses. 2010; 74:555-563.
32. Santarelli DM, Beveridge NJ, Tooney PA and Cairns 
MJ. Upregulation of dicer and microRNA expression in 
the dorsolateral prefrontal cortex Brodmann area 46 in 
schizophrenia. Biological psychiatry. 2011; 69:180-187.
33. Weinberger DR. Implications of normal brain development 
for the pathogenesis of schizophrenia. Archives of general 
psychiatry. 1987; 44:660-669.
34. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum 
JD, Haroutunian V and Fienberg AA. Genome-wide 
expression analysis reveals dysregulation of myelination-
related genes in chronic schizophrenia. Proceedings of 
the National Academy of Sciences of the United States of 
America. 2001; 98:4746-4751.
35. Stephan KE, Baldeweg T and Friston KJ. Synaptic plasticity 
and dysconnection in schizophrenia. Biological psychiatry. 
2006; 59:929-939.
36. Henry BL, Minassian A, Young JW, Paulus MP, Geyer 
MA and Perry W. Cross-species assessments of motor 
and exploratory behavior related to bipolar disorder. 
Neuroscience and biobehavioral reviews. 2010; 34:1296-
1306.
37. Jones KA and Thomsen C. The role of the innate immune 
system in psychiatric disorders. Molecular and cellular 
neurosciences. 2013; 53:52-62.
38. Orom UA, Derrien T, Beringer M, Gumireddy K, Gardini 
A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q, 
Guigo R and Shiekhattar R. Long noncoding RNAs with 
enhancer-like function in human cells. Cell. 2010; 143:46-
58.
39. O’Dushlaine C, Kenny E, Heron E, Donohoe G, Gill M, 
Morris D, International Schizophrenia C and Corvin A. 
Molecular pathways involved in neuronal cell adhesion 
and membrane scaffolding contribute to schizophrenia and 
bipolar disorder susceptibility. Molecular psychiatry. 2011; 
16:286-292.
40. Hsu WY, Lane HY, Lin CL and Kao CH. A population-
based cohort study on deep vein thrombosis and pulmonary 
embolism among schizophrenia patients. Schizophrenia 
research. 2015; 162:248-252.
41. Cotter D, Hudson L and Landau S. Evidence for 
orbitofrontal pathology in bipolar disorder and major 
depression, but not in schizophrenia. Bipolar disorders. 
2005; 7:358-369.
42. Katsel P, Davis KL, Gorman JM and Haroutunian V. 
Variations in differential gene expression patterns across 
multiple brain regions in schizophrenia. Schizophrenia 
research. 2005; 77:241-252.
43. Craddock N, O’Donovan MC and Owen MJ. Genes for 
schizophrenia and bipolar disorder? Implications for 
psychiatric nosology. Schizophrenia bulletin. 2006; 32:9-
16.
44. Dixon JR, Jung I, Selvaraj S, Shen Y, Antosiewicz-Bourget 
JE, Lee AY, Ye Z, Kim A, Rajagopal N, Xie W, Diao Y, 
Liang J, Zhao H, Lobanenkov VV, Ecker JR, Thomson JA, 
et al. Chromatin architecture reorganization during stem cell 
differentiation. Nature. 2015; 518:331-336.
45. Bomont P, Cavalier L, Blondeau F, Ben Hamida C, Belal S, 
Tazir M, Demir E, Topaloglu H, Korinthenberg R, Tuysuz 
B, Landrieu P, Hentati F and Koenig M. The gene encoding 
gigaxonin, a new member of the cytoskeletal BTB/kelch 
repeat family, is mutated in giant axonal neuropathy. Nature 
genetics. 2000; 26:370-374.
46. Boizot A, Talmat-Amar Y, Morrogh D, Kuntz NL, Halbert 
C, Chabrol B, Houlden H, Stojkovic T, Schulman BA, 
Rautenstrauss B and Bomont P. The instability of the 
BTB-KELCH protein Gigaxonin causes Giant Axonal 
Neuropathy and constitutes a new penetrant and specific 
diagnostic test. Acta neuropathologica communications. 
2014; 2:47.
47. Sarah M. Clinton SA, Vahram Haroutunian, Kenneth Davis, 
James H. Meador-Woodruff. Neurofilament subunit protein 
abnormalities in the thalamus in schizophrenia. Thalamus & 
Related Systems. 2004; Volume 2:Pages 265-272.
48. Peirce TR, Bray NJ, Williams NM, Norton N, Moskvina 
V, Preece A, Haroutunian V, Buxbaum JD, Owen MJ and 
O’Donovan MC. Convergent evidence for 2’,3’-cyclic 
nucleotide 3’-phosphodiesterase as a possible susceptibility 
gene for schizophrenia. Archives of general psychiatry. 
2006; 63:18-24.
49. Aberg K, Saetre P, Lindholm E, Ekholm B, Pettersson U, 
Adolfsson R and Jazin E. Human QKI, a new candidate 
gene for schizophrenia involved in myelination. American 
journal of medical genetics Part B, Neuropsychiatric 
genetics. 2006; 141B:84-90.
50. Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen KL, 
Brown M, Blazar BR, Abramson SB, Lafaille JJ and Dustin 
ML. Protein kinase C-theta mediates negative feedback on 
regulatory T cell function. Science. 2010; 328:372-376.
51. Tan SL, Zhao J, Bi C, Chen XC, Hepburn DL, Wang J, 
Sedgwick JD, Chintalacharuvu SR and Na S. Resistance to 
experimental autoimmune encephalomyelitis and impaired 
Oncotarget71098www.impactjournals.com/oncotarget
IL-17 production in protein kinase C theta-deficient mice. 
Journal of immunology. 2006; 176:2872-2879.
52. Gobert RP, Joubert L, Curchod ML, Salvat C, Foucault 
I, Jorand-Lebrun C, Lamarine M, Peixoto H, Vignaud C, 
Fremaux C, Jomotte T, Francon B, Alliod C, Bernasconi 
L, Abderrahim H, Perrin D, et al. Convergent functional 
genomics of oligodendrocyte differentiation identifies 
multiple autoinhibitory signaling circuits. Molecular and 
cellular biology. 2009; 29:1538-1553.
53. Serretti A and Mandelli L. The genetics of bipolar disorder: 
genome ‘hot regions,’ genes, new potential candidates and 
future directions. Molecular psychiatry. 2008; 13:742-771.
54. Yasuda R, Sabatini BL and Svoboda K. Plasticity of 
calcium channels in dendritic spines. Nature neuroscience. 
2003; 6:948-955.
55. Hahn CG, Gomez G, Restrepo D, Friedman E, Josiassen 
R, Pribitkin EA, Lowry LD, Gallop RJ and Rawson NE. 
Aberrant intracellular calcium signaling in olfactory 
neurons from patients with bipolar disorder. The American 
journal of psychiatry. 2005; 162:616-618.
56. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, 
Khanlou N, Han M, Liew CC and Tsuang MT. Comparative 
gene expression analysis of blood and brain provides 
concurrent validation of SELENBP1 up-regulation in 
schizophrenia. Proceedings of the National Academy of 
Sciences of the United States of America. 2005; 102:15533-
15538.
57. Fernandes BS, Gama CS, Cereser KM, Yatham LN, Fries 
GR, Colpo G, de Lucena D, Kunz M, Gomes FA and 
Kapczinski F. Brain-derived neurotrophic factor as a state-
marker of mood episodes in bipolar disorders: a systematic 
review and meta-regression analysis. Journal of psychiatric 
research. 2011; 45:995-1004.
58. Torrey EF, Webster M, Knable M, Johnston N and 
Yolken RH. The stanley foundation brain collection and 
neuropathology consortium. Schizophrenia research. 2000; 
44:151-155.
59. Xiao Y, Camarillo C, Ping Y, Arana TB, Zhao H, 
Thompson PM, Xu C, Su BB, Fan H, Ordonez J, Wang 
L, Mao C, Zhang Y, Cruz D, Escamilla MA, Li X, et al. 
The DNA methylome and transcriptome of different brain 
regions in schizophrenia and bipolar disorder. PloS one. 
2014; 9:e95875.
60. Trapnell C, Pachter L and Salzberg SL. TopHat: discovering 
splice junctions with RNA-Seq. Bioinformatics. 2009; 
25:1105-1111.
61. Anders S, Pyl PT and Huber W. HTSeq—a Python 
framework to work with high-throughput sequencing data. 
Bioinformatics. 2015; 31:166-169.
62. Gene Ontology C. The Gene Ontology in 2010: extensions 
and refinements. Nucleic acids research. 2010; 38:D331-
335.
63. Falcon S and Gentleman R. Using GOstats to test gene lists 
for GO term association. Bioinformatics. 2007; 23:257-258.
64. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega 
B, Regev A and Rinn JL. Integrative annotation of human 
large intergenic noncoding RNAs reveals global properties 
and specific subclasses. Genes & development. 2011; 
25:1915-1927.
65. Schizophrenia Working Group of the Psychiatric Genomics 
C. Biological insights from 108 schizophrenia-associated 
genetic loci. Nature. 2014; 511:421-427.
66. Psychiatric GCBDWG. Large-scale genome-wide 
association analysis of bipolar disorder identifies a new 
susceptibility locus near ODZ4. Nature genetics. 2011; 
43:977-983.
67. Chavez L, Jozefczuk J, Grimm C, Dietrich J, Timmermann 
B, Lehrach H, Herwig R and Adjaye J. Computational 
analysis of genome-wide DNA methylation during the 
differentiation of human embryonic stem cells along the 
endodermal lineage. Genome research. 2010; 20:1441-
1450.
68. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren 
B, Milosavljevic A, Meissner A, Kellis M, Marra MA, 
Beaudet AL, Ecker JR, Farnham PJ, Hirst M, Lander 
ES, Mikkelsen TS and Thomson JA. The NIH Roadmap 
Epigenomics Mapping Consortium. Nature biotechnology. 
2010; 28:1045-1048.
69. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, 
Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W 
and Liu XS. Model-based analysis of ChIP-Seq (MACS). 
Genome biology. 2008; 9:R137.
